2-amino-4,6-dichlorobenzoic acid methyl ester | 147494-04-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-4,6-dichlorobenzoic acid methyl ester
• 英文别名: methyl 3,5-dichloroanthranilate；4,6-dichloro-2-aminobenzoic acid methyl ester；methyl 2-amino-4,6-dichlorobenzoate；4,6-dichloroanthranilic acid methyl ester；4,6-dichloranthranilic acid methyl ester
• CAS: 147494-04-0
• 化学式: C₈H₇Cl₂NO₂
• 分子量: 220.055
• InChiKey: HPOHZHUZBACNRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2-amino-4,6-dichlorobenzoic acid methyl ester 生成 7,9-dichloro-3,4-dihydro-2H-oxazino[3,2-b]quinazolin-10-one
  参考文献：
  名称：

  REISNER D. B.; LUDWIG B. J.; SIMON E.; DEJNEKA T.; SOFIA R. D., ARZNEIMITTEL-FORSCH. , 1977, 27 NO 4, 766-770

  摘要：

  DOI：
• 作为产物：
  描述：

  4,6-dichloroisatoic anhydride 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 以92.1%的产率得到2-amino-4,6-dichlorobenzoic acid methyl ester
  参考文献：
  名称：

  Pyridazinedione compounds useful in treating neurological disorders

  摘要：

  本发明涉及吡啶并[4,5-b]喹啉及其药用盐，它们是兴奋性氨基酸拮抗剂，在需要此类拮抗作用时非常有用，例如在治疗神经系统疾病时。该发明还提供含有吡啶并[4,5-b]喹啉作为活性成分的药物组合物，以及治疗神经系统疾病的方法。

  公开号：

  US05599814A1

文献信息

• 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
  申请人：Seong Churlmin

  公开号：US20060084676A1

  公开（公告）日：2006-04-20

  The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.

  本发明涉及作为5HT6受体拮抗剂的3-芳基-3-甲基喹啉-2,4-二酮化合物，其制备方法以及含有该化合物的用于治疗中枢神经系统疾病的药物组合物。根据本发明的3-芳基-3-甲基喹啉-2,4-二酮化合物可用于治疗与5HT6受体相关的疾病，因为其对5HT6受体具有优异的结合亲和力，并且对5HT6受体具有优异的选择性，而且相对于其他受体具有优异的选择性。
• 3-heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1H)-quinolone
  申请人：Ciba-Geigy Corporation

  公开号：US05633379A1

  公开（公告）日：1997-05-27

  3-Heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1H)quinolone derivatives of formula I ##STR1## wherein the radicals R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently of the others hydrogen, an aliphatic hydrocarbon radical, free or etherified hydroxy, mercapto or etherified and/or oxidised mercapto, unsubstituted or aliphaticaliy substituted amino, nitro, free or esterified or amidated carboxy, cyano, free or amidated sulfamoyl, halogen or trifluoromethyl, X is oxy or optionally oxidised thio, A is a divalent aliphatic radical and R.sub.5 is an optionally partially hydrogenated aryl or heteroaryl radical that is unsubstituted or substituted by aliphatic or araliphatic hydrocarbon radicals, by free or etherified hydroxy, by mercapto or etherified and/or oxidised mercapto, by unsubstituted or aliphatically substituted amino, by aliphatic acyl, by free or esterified or amidated carboxy, by cyano, by free or amidated sulfamoyl, by halogen and/or by trifluoromethyl; free or etherified hydroxymethyl; cyano; or free or esterified or amidated carboxy, and tautomers and/or salts thereof, have antagonistic properties with respect to excitatory amino acids and can be used for the treatment of pathological conditions that are responsive to glycine-antagonistic blocking of NMDA-sensitive receptors.

  公式I的3-杂原基脂肪基和3-杂(芳基)脂肪基-2(1H)喹啉酮衍生物，其中基团R.sub.1、R.sub.2、R.sub.3和R.sub.4各自独立地是氢、脂肪烃基、游离或醚化的羟基、巯基或醚化和/或氧化的巯基、未取代或脂肪基取代的氨基、硝基、游离或酯化或酰胺化的羧基、氰基、游离或酰胺化的磺胺基、卤素或三氟甲基，X是氧或可选择氧化的硫，A是二价脂肪基，R.sub.5是未取代或被脂肪或芳基脂肪基取代、游离或醚化的羟基、巯基或醚化和/或氧化的巯基、未取代或脂肪基取代的氨基、脂肪酰基、游离或酯化或酰胺化的羧基、氰基、游离或酰胺化的磺胺基、卤素和/或三氟甲基取代的可选择部分氢化的芳基或杂原基脂肪基，游离或醚化的羟甲基；氰基；或游离或酯化或酰胺化的羧基，以及其互变异构体和/或盐，具有对兴奋性氨基酸的拮抗性质，并可用于治疗对甘氨酸-拮抗性NMDA敏感受体的阻断有反应的病理条件。
• 3-aryl-3-methyl-quinoline-2,4-diones, preparation method thereof and pharmaceutical composition containing same
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP1650190A1

  公开（公告）日：2006-04-26

  The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones , or a pharmaceutically acceptable salt thereof acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders because of its excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors.

  本发明涉及3-芳基-3-甲基喹啉-2,4-二酮化合物或其药用可接受盐，作为5HT6受体拮抗剂，其制备方法以及含有该化合物的用于治疗中枢神经系统疾病的药物组合物。根据本发明的3-芳基-3-甲基喹啉-2,4-二酮化合物可用于治疗与5HT6受体相关的疾病，因为其对5HT6受体具有优异的结合亲和力，并且对于其他受体具有优异的选择性。
• Synthesis and Evaluation of Benzoquinolinone Derivatives as SARS-CoV 3CL Protease Inhibitors
  作者：Tae-Young Ahn、Chih-Jung Kuo、Hun-Ge Liu、Deok-Chan Ha、Po-Huang Liang、Young-Sik Jung

  DOI：10.5012/bkcs.2010.31.01.087

  日期：2010.1.20

  For the discovery of new antivirals against Severe Acute Respiratory Syndrome-coronavirus (SARS-CoV), we prepared and evaluated several benzoquinoline compounds as its 3C-like protease (3CLpro) inhibitors. Based on the computer modeling study that each of the two rigid benzoquinolinone and N-phenoltetrazole moieties of the compound 1 is bound to the S1 and S2 sites, respectively, of the SARS protease by forming H-bonds and hydrophobic interactions, we designed and synthesized alkylated benzoquinolines at both the sites of the hydroxyl groups. We found that the compound 2a showed five times higher inhibiting activity against the 3CLpro compared to the compound 1.

  为了发现抗严重急性呼吸系统综合征-冠状病毒（SARS-CoV）的新抗病毒药物，我们制备并评估了几种苯并喹啉化合物作为其 3C 样蛋白酶（3CLpro）抑制剂。根据计算机模型研究，化合物 1 的两个刚性苯并喹啉酮和 N-苯并四唑分子分别通过形成 H 键和疏水相互作用与 SARS 蛋白酶的 S1 和 S2 位点结合，因此我们在羟基的两个位点上设计并合成了烷基化的苯并喹啉类化合物。我们发现，化合物 2a 对 3CLpro 的抑制活性是化合物 1 的五倍。
• Pyridazinedione compounds useful in the treating neurological disorders
  申请人：Imperial Chemical Industries PLC

  公开号：US05733910A1

  公开（公告）日：1998-03-31

  The present invention relates to pyridazino\x9b4,5-b!quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino\x9b4,5-b!quinolines as active ingredient, and methods for the treatment of neurological disorders.

  本发明涉及吡啶并[4,5-b]喹啉及其药用盐，其为兴奋性氨基酸拮抗剂，在需要这种拮抗作用时，如治疗神经系统疾病时，具有有用性。本发明还提供含有吡啶并[4,5-b]喹啉作为活性成分的制药组合物，以及治疗神经系统疾病的方法。